箇(ge)人(ren)簡歷(li)

2007年(nian)畢業于(yu)華中(zhong)科(ke)技(ji)大(da)學(xué)，獲醫(yī)學(xué)博士學(xué)位。2007年(nian)始在(zai)浙江(jiang)大(da)學(xué)醫(yī)學(xué)院附屬婦産(chan)科(ke)醫(yī)院從(cong)事臨牀(chuang)、科(ke)研工(gong)作(zuò)。2015-2017年(nian)作(zuò)爲(wei)訪問學(xué)者在(zai)美國(guo)國(guo)立健康研究院進(jin)行研修，主(zhu)要從(cong)事卵巢癌藥物(wù)篩選方(fang)面的(de)研究。至今髮(fa)表論文(wén)10餘篇，主(zhu)持國(guo)傢(jia)自然科(ke)學(xué)基金3項(xiang)。

主(zhu)持課題

腳手架蛋白NEDD9在(zai)宮頸癌細胞衰老中(zhong)的(de)作(zuò)用(yong)及(ji)其分(fēn)子(zi)機(jī)製(zhi)（國(guo)傢(jia)自然科(ke)學(xué)基金）

腳手架蛋白NEDD9調節(jie)TGF-β在(zai)宮頸癌細胞上皮間質(zhi)轉化中(zhong)的(de)作(zuò)用(yong)及(ji)其分(fēn)子(zi)機(jī)製(zhi)（國(guo)傢(jia)自然科(ke)學(xué)基金）

質(zhi)子(zi)泵抑製(zhi)劑調節(jie)mTOR信(xin)号通(tong)路介導(dao)的(de)自噬在(zai)卵巢癌順鉑耐藥中(zhong)的(de)機(jī)製(zhi)研究（國(guo)傢(jia)自然科(ke)學(xué)基金）

研究方(fang)向

婦科(ke)腫瘤

代(dai)表論文(wén)

1. Wu Q, Wang L, Zhao X, Tian Q, Wang F, Sima N, Qiu L, Lu W, Xie X, Wang X, Cheng X. The Value of MicroRNA-375 Detection for Triaging Primary Human Papillomavirus Positive Women: A Cross-Sectional Study in a General Population. Front Oncol. 2021;11:771053.

2. Gorshkov K, Sima N, Sun W, Lu B, Huang W, Travers J, Klumpp-Thomas C, Michael SG, Xu T, Huang R, Lee EM, Cheng X, Zheng W. Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. Transl Oncol. 2019;12(3):441-452.

3. Sima N, Sun W, Gorshkov K, Shen M, Huang W, Zhu W, Xie X, Zheng W, Cheng X. Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. Transl Oncol. 2018;11(4):1053-1064.

4. Sima N, Li R, Huang W, Xu M, Beers J, Zou J, Titus S, Ottinger EA, Marugan JJ, Xie X, Zheng W. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet J Rare Dis. 2018;13(1):54.

5. Sima N, Cheng X, Ye F, Ma D, Xie X, Lü W. The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC. PLoS One. 2013;8(9):e74594. 

6. Sima N, Lü W, Xie X. Early proteins E6 and E7 of human papillomavirus may attenuate ischemia-reperfusion injury. Med Hypotheses. 2011;76(4):607-9.